Inhibition of Mac-1 receptor binding to fibrinogen using D.sub.30 homologs
AssigneeThe Scripps Research Institute
InventorsDario C. Altieri, Edward F. Plow, Thomas S. Edgington
Life of this patent
Estimating the term…
Abstract
The present invention contemplates therapeutic compositions containing a D.sub.30 homolog capable of binding to the Mac-1 receptor D.sub.30 binding site and inhibiting fibrinogen binding to the Mac-1 receptor via the D.sub.30 binding site, Methods of inhibiting Mac-1 receptor binding to any Mac-1 ligand and methods of inhibiting Mac-1 receptor mediated inflammation within a patient by administering a D.sub.30 homolog are also contemplated,
Claims2
An isolated, purified polypeptide having a length of no more than 150 amino acid residues, which polypeptide is a fragment of the D.sub.30 region of the gamma chain of fibrinogen (SEQ ID NO 3), wherein said fragment includes an amino acid residue sequence represented by the formula --QKRLDGS--, said sequence shown in SEQ ID NO 3 from residue 195 to residue 201.
Dependencies are inferred from the claim text.